Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
Indications Ulcerative colitis
Focus Registrational; Therapeutic Use
Acronyms LUCENT 2
Sponsors Eli Lilly and Company

Most Recent Events

04 Feb 2025 Status changed from active, no longer recruiting to completed.
20 Dec 2024 Planned End Date changed from 20 Dec 2024 to 1 Dec 2024.
05 Dec 2024 Results evaluating clinical response, baseline characteristics and clinical status published in the Inflammatory Bowel Diseases.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com